Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" google.com

The OncFive: Top Oncology Articles for the Week of 1/4

google.com·18w

Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms

google.com·18w

FDA Grants Orphan Drug Designation to CK0804 for Myelofibrosis

google.com·18w

YM Biosciences investment case centers on CYT387; analysts view

google.com·18w

S*BIO's JAK2 inhibitor SB1518 granted orphan status by European Commission for myelofibrosis

google.com·18w

Novartis' Tasigna approved in Japan; JAK inhibitor INC424 meets primary Ph III endpoint

google.com·18w

UK's NICE says no to Novartis' Jakavi for enlarged spleen

google.com·18w

Top Biotech Players REGN, INCY, PTCT Among Participants At J.P.Morgan Healthcare ...

google.com·18w

Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy

google.com·19w

Cellarity Provides Strategic Priorities and Outlook for 2026

google.com·19w

Living Boldly: Celebrities With Essential Thrombocythemia

google.com·19w

Polycythemia Vera Pipeline and Drug Development in 2025: 10+

google.com·19w

Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer

google.com·19w

FINDING PURPOSE

google.com·19w

New Treg Therapy Earns FDA Orphan Drug Designation in Myelofibrosis

google.com·19w

Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis ...

google.com·19w

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236

google.com·19w

The Assistance Fund Opens New Program for Myeloproliferative Neoplasms

google.com·19w

The Assistance Fund Opens New Program for Myeloproliferative Neoplasms

google.com·19w

CK0804 Receives FDA Orphan Drug Designation for Myelofibrosis

google.com·19w

Log in to enable infinite scrolling